The half-lives of neutrophils in the blood and lungs of patients with cystic fibrosis - HANCO

niversitair Medisch Centrum Utrecht0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•Age > 18 years and younger than 50 years
•Healthy without indications of any inflammatory disease
•Written informed consent;CF patients without treatment wtih corticosteroids
•Age > 18 and younger than 50 years
•Diagnosis of CF by clinical symptoms and positive sweat tests (sweat Cl- concentration > 60 mmol/l) and/or disease causing mutation(s) in the CFTR gene
•Being clinically stable and on steady concomitant therapy at least four weeks prior to the study
•FEV1 > 30% of predicted
•written informed consent;CF patients on treatment wtih corticosteroids
•Diagnosis of CF by clinical symptoms and positive sweat tests (sweat Cl- concentration > 60 mmol/l) and/or disease causing mutation(s) in the CFTR gene
•Being clinically stable and on steady concomitant therapy at least four weeks prior to the study
•FEV1 > 30% of predicted
•inhalation of fluticasone proprionate (or equivalent) >400 microg total daily for at least 2 weeks prior to the study.
•written informed consent

•Any infection
•Auto-immune disease
•Use of medication, excluding: anticonceptives and pain killers (used less than once a week)
•exuberant alcohol consumption (for males > 36 glasses per week, for females > 24 glasses per week)
•drugs abuse
•History of cancer

发起方

niversitair Medisch Centrum Utrecht